Summary of Study ST002251
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001439. The data can be accessed directly via it's Project DOI: 10.21228/M8QD9Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002251 |
| Study Title | Untargeted metabolomics on plasma from children with asthma, comparing exacerbation-prone to non-exacerbation-prone |
| Study Type | Untargeted MS |
| Study Summary | Background: Some children with asthma remain poorly controlled and have recurrent exacerbations despite treatment with inhaled corticosteroids. Aside from prior exacerbations, there are currently no reliable predictors of exacerbation-prone asthma in these children and limited understanding of potential underlying mechanisms. Objective: We sought to quantify small molecules in the plasma of children with exacerbation- prone asthma through mass spectrometry-based metabolomics. We hypothesized that the plasma metabolome of these children would differ from that of children with non-exacerbation- prone asthma. Methods: Plasma metabolites were extracted from four pediatric asthma cohorts (n=215 total, n=41 with exacerbation-prone asthma) and detected using a ZIC-HILIC column coupled to a Q Exactive HF mass spectrometer. High-confidence annotations were retained for univariate analysis and were confirmed by a sensitivity analysis in subjects on high-dose inhaled corticosteroids. Metabolites that varied by cohort were excluded. Metaboanalyst was used to identify pathways of interest. Concentrations were calculated by reference standardization to NIST SRM 1950. Results: We identified 32 unique, cohort-independent metabolites that differed in children with exacerbation-prone asthma compared to children with non-exacerbation-prone asthma. Comparison of metabolite concentrations to literature-reported values for healthy children revealed that most metabolites were decreased in both asthma groups, but more so in exacerbation-prone asthma. Pathway analysis identified arginine, lysine, and methionine pathways as most impacted. Conclusions: Several plasma metabolites are perturbed in children with exacerbation-prone asthma and are largely related to arginine, lysine, and methionine pathways. While validation is needed, plasma metabolites may be potential biomarkers for exacerbation-prone asthma in children. |
| Institute | Emory University |
| Department | Pediatrics |
| Laboratory | Joshua Chandler, PhD |
| Last Name | Chandler |
| First Name | Joshua |
| Address | 2015 Upper Gate Drive NE, Atlanta, GA 30322 |
| joshua.chandler@emory.edu | |
| Phone | 404-727-3536 |
| Submit Date | 2022-07-25 |
| Num Groups | 2 |
| Total Subjects | 215 |
| Num Males | 135 |
| Num Females | 80 |
| Publications | JACI-D-22-00220 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-01-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU002337 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 6-17 years |
| Weight Or Weight Range: | Non-exacerbation-prone IQR: 30-68 kg; Exacerbation-prone IQR: 42-63 kg |
| Height Or Height Range: | Non-exacerbation-prone IQR: 131-165 cm; Exacerbation-prone IQR: 140-163 cm |
| Gender: | Male and female |
| Human Race: | 18 white, 189 Black, 7 more than one race, 1 Asian |
| Human Ethnicity: | 2 Hispanic, 113 Not Hispanic |
| Human Medications: | 92 on high-dose inhaled corticosteroids; 94 on long-acting beta adrenergic receptor agonists; 111 on Montelukast |
| Human Smoking Status: | 24 exposed to tobacco smoke |
| Human Inclusion Criteria: | 1) current or historical evidence of >=12% reversibility in forced expiratory volume in one second (FEV1) relative to baseline after bronchodilator administration; 2) airway hyperresponsiveness to methacholine, with a provocative concentration of methacholine causing a 20% drop in FEV1 |
| Human Exclusion Criteria: | 1) premature birth before 35 weeks of gestation; 2) other chronic airway disorders that could mimic asthma. |
